Abbott Gains 0.81% on Diagnostic and Diabetes Care Momentum Ranks 110th in $760M Trading Day

. 12, , . equity market for the day. The stock’s performance was driven by recent developments in its healthcare product pipeline and strategic partnerships. Analysts noted that the company’s focus on expanding its diagnostic solutions and diabetes care segments contributed to investor confidence.

Recent reports highlighted Abbott’s progress in securing regulatory approvals for its next-generation glucose monitoring systems, which are expected to strengthen its market position in the growing continuous glucose monitoring (CGM) sector. Additionally, the firm’s collaboration with regional healthcare providers to enhance distribution networks in emerging markets added momentum to its stock. Investors appeared to price in these near-term catalysts, which align with Abbott’s long-term revenue growth targets.

To run this back-test accurately I need to pin down a few practical details about the investment universe and execution assumptions: 1. Universe • Do you want to rank every U.S. listed common stock each day, or restrict the pool (e.g., current S&P 500 constituents, Russell 3000, NASDAQ + NYSE only, etc.)? • Should ADRs, ETFs and preferred shares be excluded? 2. Ranking / Re-balancing convention • Rank by that day’s dollar trading volume calculated on the close? (Most common) • Buy the 500 highest-volume names at the next session’s open and liquidate them at that day’s close (i.e., a 1-day holding period)? 3. Weighting & costs • Equal-weight each of the 500 positions? • Any commission or slippage assumption, or ignore trading costs? 4. Benchmark (optional) • Would you like to see results versus, say, SPY? Once I have these items settled I can generate the data-retrieval plan and run the back-test.